Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03490240
Other study ID # 170609001
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 1, 2018
Est. completion date December 31, 2024

Study information

Verified date December 2023
Source University of Alabama at Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized controlled trial will examine the effect of a 6-month behavioral intervention, based on social cognitive theory and delivered through the Internet, for increasing physical activity and secondarily improving mobility, cognition, symptoms and quality of life in persons with MS. The investigators hypothesize that individuals who receive the 6-month behavioral intervention will demonstrate an increase in physical activity behavior that will last throughout a 6-month follow up compared with participants in the control condition. The investigators further hypothesize that individuals in the behavioral intervention will demonstrate better walking mobility and cognitive function, reduced fatigue, depression, anxiety, and pain, and improved quality of life compared to the control condition. The investigators hypothesize that the behavioral intervention will increase physical activity through positive changes in self-efficacy, outcome expectations, goal setting, and impediments as social-cognitive determinants.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 280
Est. completion date December 31, 2024
Est. primary completion date March 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria: - Diagnosis of MS - Relapse free in the past 30 days - Internet and email access - Willingness to complete the questionnaires, wear the accelerometer, and undergo randomization - Being non-active defined as not engaging in regular activity (30 minutes accumulated per day) on more than 2 days of the week during the previous six months - Ability to ambulate with or without assistance (i.e. walking with or without a can or walker, but not a wheelchair) - Age between 18 and 64 Exclusion Criteria: - Moderate or high risk for undertaking strenuous or maximal exercise per participants response to the PAR-Q. Those who report no more than one YES or affirmative on the 7 item PAR-Q will be considered at low risk and included for participation. All others will be considered at moderate or high risk and excluded from participation.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
BIPAMS
The primary content of the website is delivered through interactive video courses. The interactive video courses are released seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention. Another key part of the website is the Tracker feature. This feature allows for tracking of daily step counts (via Yamax SW-200 pedometer) as well as setting goals and monitoring progress over the program. The one-on-one video chats are conducted face to face through skype and are semi-scripted. The chats consist of an ongoing review of goal-setting and progress toward goal attainment through Tracker as well as discussion of strategies and facilitators of behavioral change based on SCT and current website content. The chats occur seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention.
WELLMS
The control condition focuses on self-managing MS through means other than physical activity. The materials are transformations of brochures provided by the NMSS, including Gait or Walking Problems: The Basic Facts; MS and Your Emotions; Pain: The Basic Facts; Solving Cognitive Problems; Taming Stress in MS; Food for Thought: MS and Nutrition; and Vitamins, Minerals, and Herbs: An Introduction. The delivery of the Internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition, and will have a comparable time commitment. The control condition will account for attention and social contact as well as other possible biases such as initial reactivity and time spent on the website and video chats. The participants in the control condition will not be offered the behavioral intervention for increasing physical activity after completion of the study procedures.

Locations

Country Name City State
United States Exercise Neuroscience Research Lab Birmingham Alabama

Sponsors (2)

Lead Sponsor Collaborator
University of Alabama at Birmingham National Multiple Sclerosis Society

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes of self-report measures based on Social Cognitive Theory on Self-Efficacy through the MS Self-Efficacy Sale at 6 and 12 months from baseline. Self report measures for self-efficacy will be assessed through the MS Self-Efficacy scale. Participants will complete this questionnaire at baseline, 6 month, and 12 months Baseline through 12 months
Other Changes of self-report measures based on Social Cognitive Theory on Self-Efficacy through the Exercise Self-Efficacy Scale at 6 and 12 months from baseline. Self report measures for self-efficacy will be assessed through the Exercise Self-Efficacy Scale. Participants will complete this questionnaire at baseline, 6 month, and 12 months Baseline through 12 months
Other Changes of self-report measures based on goal setting through the Exercise Goal Setting and Planning Scale at 6 and 12 months from baseline. Self report measures for goal setting will be assessed through the Exercise Goal Setting and Planning Scale. Participants will complete this questionnaire at baseline, 6 month, and 12 months Baseline through 12 months
Other Changes of self-report measures based on outcome expectations through the Multidimensional Outcome Expectancies for Exercise Scale at 6 and 12 months from baseline. Self report measures for outcome expectations will be assessed through the Multidimensional Outcome Expectancies for Exercise Scale. Participants will complete this questionnaire at baseline, 6 month, and 12 months Baseline through 12 months
Other Changes of self-report measures based on quality of life through the Late-Life Function and Disability Inventory at 6 and 12 months from baseline. Self report measures for quality of life will be assessed through the Late-Life Function and Disability Inventory. Participants will complete this questionnaire at baseline, 6 month, and 12 months Baseline through 12 months
Other Changes of self-report measures based on quality of life through the Social Provisions Scale Inventory at 6 and 12 months from baseline. Self report measures for quality of life will be assessed through the Social Provisions Scale. Participants will complete this questionnaire at baseline, 6 month, and 12 months Baseline through 12 months
Primary Change of Physical Activity levels through Accelerometery from baseline at 6 and 12 months. Physical activity will be assessed using an ActiGraph accelerometer. Participants will wear an accelerometer on a belt around their waist during the waking hours of a 7 day period. Participants will complete this at baseline, 6 months, and 12 months. Baseline through 12 months
Primary Change of Physical Activity levels through the Godin Leisure-Time Exercise Questionnaire from baseline at 6 and 12 months. Physical activity will be assessed using the Godin Leisure-Time Exercise Questionnaire. Participants will complete this questionnaire at baseline, 6 months, and 12 months. Baseline through 12 months.
Primary Change of Physical Activity levels through the Abbreviated International Physical Activity Questionnaire from baseline at 6 and 12 months. Physical activity will be assessed using the Abbreviated International Physical Activity Questionnaire. Participants will complete this questionnaire at baseline, 6 months, and 12 months. Baseline through 12 months.
Secondary Change of self-report measures of walking through the Multiple Sclerosis Walking Scale - 12 from baseline at 6 and 12 months Self report measures of walking will be assessed through the Multiple Sclerosis Walking Scale - 12. Participants will complete this questionnaire at baseline, 6 month, and 12 months. Baseline through 12 months
Secondary Change of self-report measures of Walking through the Patient Determined Disease Steps Scale from baseline at 6 and 12 months. Self report measures of walking will be assessed through the Patient Determined Disease Steps Scale. Participants will complete this questionnaire at baseline, 6 month, and 12 months. Baseline through 12 months
Secondary Change of self-report measures of Cognition through the Perceived Deficits Questionnaire from baseline at 6 and 12 months. Self report measures of cognition will be assessed through the Perceived Deficits Questionnaire. Participants will complete this questionnaire at baseline, 6 month, and 12 months. Baseline through 12 months
Secondary Change of self-report measures of Cognition through the Multiple Sclerosis Neuropsychological Questionnaire from baseline at 6 and 12 months. Self report measures of cognition will be assessed through the Multiple Sclerosis Neuropsychological Questionnaire. Participants will complete this questionnaire at baseline, 6 month, and 12 months. Baseline through 12 months
Secondary Change of self-report measures of Fatigue through the Fatigue Severity Scale from baseline at 6 and 12 months. Self report measures of fatigue will be assessed through the Fatigue Severity Scale. Participants will complete this questionnaire at baseline, 6 month, and 12 months Baseline through 12 months
Secondary Change of self-report measures of Fatigue through the Modified Fatigue Impact Scale at 6 and 12 months from baseline. Self report measures of fatigue will be assessed through the Modified Fatigue Impact Scale. Participants will complete this questionnaire at baseline, 6 month, and 12 months Baseline through 12 months
Secondary Change of self-report measures of Anxiety and Depression through the Hospital Anxiety and Depression Scale at 6 months and 12 months from baseline. Self report measures of Anxiety and Depression will be assessed through the Hospital Anxiety and Depression scale. Participants will complete this questionnaire at baseline, 6 month, and 12 months Baseline through 12 months
Secondary Change of self-report measures of Pain through the Short-form of McGill Pain Questionnaire at 6 and 12 months from baseline. Self report measures of Pain will be assessed through the Short-form of McGill Pain Questionnaire. Participants will complete this questionnaire at baseline, 6 month, and 12 months Baseline through 12 months
Secondary Changes of self-report measures of sleep through the Pittsburgh Sleep Quality Index at 6 and 12 months from baseline. Self report measures of sleep will be assessed through the Pittsburgh Sleep Quality Index. Participants will complete this questionnaire at baseline, 6 month, and 12 months Baseline through 12 months
Secondary Changes of self-report measures of quality of life through the Medical Outcomes Study Short Form-36 at 6 and 12 months from baseline. Self report measures of quality of life will be assessed through the Medical Outcomes Study Short Form-36 . Participants will complete this questionnaire at baseline, 6 month, and 12 months Baseline through 12 months
Secondary Changes of self-report measures of quality of life through the Multiple Sclerosis Impact Scale-29 at 6 and 12 months from baseline. Self report measures of quality of life will be assessed through the Multiple Sclerosis Impact Scale-29. Participants will complete this questionnaire at baseline, 6 month, and 12 months Baseline through 12 months
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4